

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants :Yukio SATO et al.

Group Art Unit : 1614

Appl. No. : 10/553,948

Examiner : Nina Archie

I.A. Filed : April 23, 2004

Confirmation No. : 6527

For : METHYLATED CPG POLYNUCLEOTIDE

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner of Patents  
U.S. Patent and Trademark Office  
Customer Service Window, Mail Stop Amendment  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir:

Pursuant to 37 C.F.R. § 1.56 and 37 C.F.R. §§ 1.97-1.98 and further to the Information Disclosure Statement, filed December 4, 2006, Applicants hereby direct the Examiner's attention to a Japanese Office Action dated September 14, 2010 (copy attached) issued in connection with the counterpart Japanese application and the documents cited therein, as follows:

KALNIK et al., "O<sup>6</sup>-Ethylguanine Carcinogenic Lesions in DNA: An NMR Study of O<sup>6</sup>etG•C Pairing in Dodecanucleotide Duplexes", Biochemistry, vol. 28 (1989), pp. 6182-6192;

KAWAI et al., "Intrastrand 2'β Hydrogen Abstraction of 5'-Adjacent Deoxyguanosine by Deoxyuridin-5-yl in Z-form DNA", Tetrahedron Letters, vol. 40 (1999), pp. 2589-2592;

LEE et al., "DNA Microstructural Requirements for Neocarzinostatin Chromophore-induced Direct Strand Cleavage", Nucleic Acids Research, vol. 17, no. 14 (1989), pp. 5809-5824 (apparently 5809-5825);

WO 01/75092;

WO 02/074318; and

WO 00/38693

Applicants note that US 2004/0097465 A1 is a family member of WO 02/074318 and U.S. Patent No. 6,579,860 is a family member of WO 00/38693.

Copies of the above-listed documents (with the exception of the U.S. patent and the U.S. patent application publication and the previously cited Kalnik et al., Kawai et al. and Lee et al.) are enclosed together with a completed copy of a form listing these documents. Accordingly, the Examiner is requested to consider these documents and to indicate such consideration by returning a signed copy of the form with the next communication from the Patent and Trademark Office.


In accordance with 37 C.F.R. 1.97(e), the undersigned hereby states that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Of course, this statement does not apply to information that has previously been cited by Applicants or the Examiner in the present application as that information is already of record and no certification is necessary. Moreover, U.S. family members of the documents cited in the Japanese Official Action are being submitted for record completion.

Moreover, this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Applicants submit herewith payment in the amount of \$180.00. If any fee is required for consideration of this disclosure statement, including any fee under 37 C.F.R. 1.17(p), Applicants hereby authorize that any required fee be charged to Deposit Account No. 19-0089.

Should the Examiner have any questions, the Examiner is invited to contact the undersigned at the below-listed telephone number.

Respectfully submitted,  
Yukio SAEKI et al.



Bruce H. Bernstein  
Reg. No. 29,027

October 14, 2010  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191

Arnold Turk  
Reg. No. 33094

{P28700 01032212.DOC}